Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...979899100101102103104105106107...123124»
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    Review, Journal:  Management and Treatment of Hepatocellular Carcinoma with Immunotherapy: A Review of Current and Future Options. (Pubmed Central) -  Aug 26, 2020   
    Immunotherapy in HCC is a relatively safe option for treating patients with advanced disease in the USA who are either unable to receive or failed sorafenib/lenvatinib therapy and thus may offer an additional survival benefit for these patients. The purpose of this review is to elaborate on some of the most recent advancements in immunotherapy.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Clinical, Journal, PD(L)-1 Biomarker, IO Biomarker:  Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma. (Pubmed Central) -  Aug 26, 2020   
    LEP is a promising alternative as a non-first-line therapeutic regimen for patients with refractory BTC. Furthermore, well-designed prospective clinical trials with a control arm are still needed to obtain more evidences to confirm the efficacy and safety of this particular regimen as well as the role of PDL1 expression.
  • ||||||||||  Stivarga (regorafenib) / Bayer, Lenvima (lenvatinib) / Eisai, Merck (MSD), Nexavar (sorafenib) / Bayer, Amgen
    Clinical, Clinical guideline, Review, Journal, IO Biomarker:  2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. (Pubmed Central) -  Aug 26, 2020   
    Novel biomarkers, imaging and operative techniques are recommended in the updated Chinese guideline. More aggressive treatment modalities are suggested for more progressed HBV-related HCC in China.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    [VIRTUAL] Q&A Symposium: Cancer care beyond anti-tumor therapy () -  Aug 25, 2020 - Abstract #ILCA2020ILCA_106;    
    LENVIMA® monotherapy in the rapidly evolving uHCC treatment landscape. This will include discussions around patient selection and clinical considerations in the first line setting as well as an overview of the latest clinical data for LENVIMA® monotherapy.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    [VIRTUAL] The evolving HCC treatment landscape: what is the role of LENVIMA® monotherapy in first-line uHCC? () -  Aug 25, 2020 - Abstract #ILCA2020ILCA_105;    
    In this symposium, Professor Andrew Zhu and Professor Arndt Vogel will discuss the role of LENVIMA® monotherapy in the rapidly evolving uHCC treatment landscape. This will include discussions around patient selection and clinical considerations in the first line setting as well as an overview of the latest clinical data for LENVIMA® monotherapy.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal, Combination therapy, Monotherapy:  Response of advanced HCC to pembrolizumab and lenvatinib combination therapy despite monotherapy failure. (Pubmed Central) -  Aug 21, 2020   
    However, it remains unclear if failure to monotherapy has an impact on combination therapy. We therefore report a patient well responding to combination therapy despite previous failures to TKI and ICI monotherapy.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Review, Journal:  Review article: new therapeutic interventions for advanced hepatocellular carcinoma. (Pubmed Central) -  Aug 20, 2020   
    There are several first-line and second-line therapeutic options available for patients with advanced HCC. Further studies are needed to determine how best to select between and sequence the growing number of therapeutic options.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  Lenvatinib and pembrolizumab in advanced gastric cancer. (Pubmed Central) -  Aug 18, 2020   
    At this point, the patient was doing well, suggesting that lenvatinib was effective in treating the MTC liver metastasis and may be one of the treatment for advanced MTC caused by C634Y mutation in the RET gene. No abstract available
  • ||||||||||  everolimus / Generic mfg., Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Retrospective data, Review, Journal:  Second-line Treatments of Advanced Hepatocellular Carcinoma: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. (Pubmed Central) -  Aug 14, 2020   
    Our study identified a new type of small-molecular inhibitors of mTOR and confirmed their ability to enhance the antitumor effect of molecular-targeted agents on advanced HCC. This network meta-analysis concludes that, based on current evidence, regorafenib could be the agent of choice in the second-line treatment of HCC, with cabozantinib as a possible alternative for sorafenib-intolerant patients.
  • ||||||||||  Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Review, Journal:  Immuno-Oncotherapeutic Approaches in Advanced Hepatocellular Carcinoma. (Pubmed Central) -  Aug 14, 2020   
    Advanced hepatocellular carcinoma has limited treatment options, but there has been extensive growth recently with cabozantinib, regorafenib, lenvatinib, nivolumab, atezolizumab, and bevacizumab, which are some of the treatments that have received FDA approval just over the last three years...The anti-PD-1 checkpoint inhibitors nivolumab and pembrolizumab have been FDA approved as a second line treatment in patients who progressed or are intolerant to Sorafenib...Other novel immune-based approaches and oncolytic viruses are in the early phases of clinical evaluation. These innovative approaches enhance the intensity of cancer-directed immune responses and will potentially impact the outlook of this aggressive disease.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment change, Metastases:  A Study of E7080 in Subjects With Advanced Thyroid Cancer (clinicaltrials.gov) -  Aug 14, 2020   
    P2,  N=51, Completed, 
    These innovative approaches enhance the intensity of cancer-directed immune responses and will potentially impact the outlook of this aggressive disease. N=37 --> 51
  • ||||||||||  dovitinib (TKI258) / Oncology Venture, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Review, Journal:  Therapeutic implications of fibroblast growth factor receptor inhibitors in a combination regimen for solid tumors. (Pubmed Central) -  Aug 13, 2020   
    Therefore, the aim of the present review is to describe the pharmacological characteristics of FGFR inhibitors that may be combined with other therapeutic agents and the preclinical data supporting their combination. Additionally, their clinical implications and the remaining challenges for FGFR inhibitor combination regimens are discussed.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment closed, Trial completion date, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker:  PLENTY202001: Pembrolizumab and LENvatinib in Participants With Hepatocellular Carcinoma (HCC) Before Liver Transplant (clinicaltrials.gov) -  Aug 10, 2020   
    P=N/A,  N=192, Active, not recruiting, 
    Trial primary completion date: Sep 2023 --> Mar 2023 Not yet recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2022
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD), Nexavar (sorafenib) / Bayer, Amgen
    Journal:  Primary Treatment with Molecular-Targeted Agents for Hepatocellular Carcinoma: A Propensity Score-matching Analysis. (Pubmed Central) -  Aug 9, 2020   
    As a primary molecular-targeted agent-based treatment for advanced HCC, our findings suggested that sorafenib is generally appropriate as it offers significantly lower frequency of adverse events and higher probability of transition to secondary treatment, in consideration of the enhanced postprogression survival mediated by sequential treatment. Alternatively, lenvatinib affords a significantly higher therapeutic effect and should be used when immediate tumor reduction is required.
  • ||||||||||  Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Clinical, PK/PD data, Review, Journal:  Clinical Pharmacokinetics and Pharmacodynamics of Transarterial Chemoembolization and Targeted Therapies in Hepatocellular Carcinoma. (Pubmed Central) -  Aug 7, 2020   
    Systemic therapy with TKIs is based on sorafenib and lenvatinib as first-line treatment and regorafenib and cabozantinib as second-line treatment...To date, only partial data supporting sorafenib monitoring is available. Results from further pharmacokinetic/pharmacodynamic studies of these four TKIs are eagerly awaited and are expected to permit such monitoring and the development of consensus guidelines.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Clinical, Journal:  Impact of Grip Strength in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib. (Pubmed Central) -  Aug 7, 2020   
    A multivariate Cox proportional hazards model showed that modified albumin-bilirubin-grade (mALBI) 2b (hazard ratio (HR) 4.39) and a decreased GS (HR 3.55) were independently associated with an increased risk of poor prognosis. In addition to the hepatic functional reserve, a decreased GS was a poor prognostic factor in lenvatinib-treated u-HCC patients.
  • ||||||||||  Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Review, Journal, IO biomarker:  Novel Targeted Therapies for Metastatic Thyroid Cancer-A Comprehensive Review. (Pubmed Central) -  Aug 6, 2020   
    Several other emerging classes of medications, such as gene fusion inhibitors and immune checkpoint inhibitors, are being actively investigated in several clinical trials. In this review, we describe the molecular landscape of thyroid cancer and novel targeted therapies and treatment combinations available for the treatment of metastatic thyroid cancer.
  • ||||||||||  Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Journal:  Optimizing Sequential Systemic Therapies for Advanced Hepatocellular Carcinoma: A Decision Analysis. (Pubmed Central) -  Aug 6, 2020   
    Three first-line (single-agent Sorafenib or Lenvatinib, and combination of Atezolizumab plus Bevacizumab) followed by five second-line treatments (Regorafenib, Cabozantinib, Ramucirumab, Nivolumab, Pembrolizumab) were compared in fifteen sequential strategies...Accordingly, the net health benefit assessed by ISER favored Lenvatinib followed by Nivolumab, compared to Atezolizumab plus Bevacizumab, followed by Nivolumab in 52% of cases. Further sequential clinical trials or large-scale real-world studies may prove useful to evaluate the net health benefit of the best sequential treatment for advanced HCC.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Biomarker, Clinical, Journal, Real-World Evidence:  Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions-Multicenter analysis. (Pubmed Central) -  Aug 4, 2020   
    Further sequential clinical trials or large-scale real-world studies may prove useful to evaluate the net health benefit of the best sequential treatment for advanced HCC. Good hepatic function (mALBI 1/2a) is the best indication for LEN, while potential appetite loss in association with low BMI should be kept in mind in such cases.